Wheeler MB, Lu M, Dillon JS, Leng XH, Chen C, and Boyd AE, 3rd
Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy
The trend of combining therapies continues to gain momentum, with growing support for pairing GLP-1 receptor agonists and SGLT2 inhibitors
It connects: Brain metabolism Liver insulin Fat tissue inflammation Hormones energy balance This systems-level approach reflects the future of medicine: treating the network, not isolated symptoms
However, without baseline metabolic assessment, genetic markers relevant to GLP-1 pathway response, or ongoing biomarker monitoring, some patients may experience suboptimal outcomes or higher side-effect burden
Dose reduction for maintenance Some researchers find that they can maintain their weight loss at a lower dose than what was needed to achieve it